BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

Daewoong and HitGen Announce Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery

HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectiv...

November 14, 2022 | News

XJTLU and University of Liverpool to inaugurate Joint Centre for Pharmacology and Therapeutics

Xi'an Jiaotong-Liverpool University (XJTLU) researchers conduct world-class biopharmaceutical research at the University's Suzhou Industrial Park (SIP) c...

November 09, 2022 | News

Himalaya Therapeutics Announces Highlights of Recent Clinical Progress

Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in NSCLC continue to show antitumor activity with additional patients enrolled HTBA3011 Undif...

November 09, 2022 | News

Merck Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in China

Merck to offer its first-to-market Blazar ® Rodent Panel for virus testing Reduces biosafety turnaround time by up to 80% Reduces animal ...

November 08, 2022 | News

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris, Completed the First Patient Dose in Phase III Trial

The study is a prospective, self-controlled, multicenter Phase Ⅲ trial aimed at investigating the additional detection rate and safety of Hexvix®&nbs...

November 07, 2022 | News

NCCN Working with Medlive to Advance High-Quality Cancer Care in China and Worldwide

The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers in the United States—is announc...

November 03, 2022 | News

Shanghai Operation Robot announced the first Robot-assisted human clinical trial of biliary stent placement surgery

The operation was performed by the team of Professor and Dr. Xiaofeng Zhang, vice president of Hangzhou First People's Hospital and director of the Ce...

November 03, 2022 | News

WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China

The facility's design incorporates environmental protection, energy conservation, emission reduction, and resource utilization – a reflection of WuXi...

October 26, 2022 | News

Chinese NMPA Approves Pivotal Phase III Study of TLX591-CDx for Prostate Cancer Imaging

The IND application was submitted in partnership with Grand Pharmaceutical Group Limited (Grand Pharma), Telix's partner in the Greater China reg...

October 17, 2022 | News

Kira Pharmaceuticals Announces IND Approval from Chinese NMPA

Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, announced today th...

October 17, 2022 | News

Merck to Support Jacobio Pharma on Clinical Trial of JAB-21822 in Combination with Cetuximab

This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer. Jacobio ...

October 13, 2022 | News

WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody

Within the partnership, Toregem BioPharma will have access to WuXi Biologics' integrated CMC services in cell line development, cell banking and testing se...

October 12, 2022 | News

China NMPA Approves Selpercatinib for the Treatment of Patients with RET-driven Lung and Thyroid Cancers

Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

October 10, 2022 | News

Sciwind Biosciences Announces Initiation of Dosing in Phase 1 Clinical Trial Evaluating XW014

Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic dis...

October 10, 2022 | News

Stay Connected